DarioHealth Corp. (DRIO:NASDAQ) announced the launch of its Integrated GLP-1 Program, the first commercial offering developed through the company's collaboration with Beluga Health. The program combines Dario's digital chronic care platform with licensed provider evaluation, prescribing of FDA-approved GLP-1 medications where clinically appropriate, and ongoing clinical oversight within a single platform.
According to the company, Dario has supported members using GLP-1 therapies through AI-powered engagement, connected monitoring, nutrition support and behavioral coaching. Through Beluga's network of licensed healthcare providers, the platform now also includes medical evaluation, prescribing and clinical oversight.
"Dario has expanded beyond the digital engagement and monitoring layer around someone else's prescription," Chief Executive Officer Erez Raphael said in a company news release. "With Beluga's clinical care infrastructure inside our platform, we deliver members the full journey: evaluation, prescription where clinically appropriate, and the chronic care management that determines whether the therapy actually works."
The company said the launch comes as employers and health plans move away from broad GLP-1 coverage toward clinically managed models. It cited data from the Business Group on Health showing that 67% of surveyed employers are covering GLP-1 medications for weight management in 2026, with 72% of those planning to continue coverage in 2027. Dario also cited the International Foundation of Employee Benefit Plans, which reported that 27% of employers encourage employees to obtain GLP-1 medications through direct-to-consumer platforms, while 21% encourage the use of employer-sponsored healthcare spending and reimbursement accounts.
According to Dario, the program is designed to be available through three channels. The company said it expects to launch through its MyDario Shop beginning in Fall 2026, noting that its digital marketplace has served more than 1 million consumers over the past three years. The program is also expected to be offered through health plan marketplaces and employer B2B2C programs.
Across all three channels, Dario said member interactions generate blinded data that its DarioIQ AI engine uses to optimize member outcomes and payer cost savings.
"GLP-1 medications deliver the greatest value when they are part of a comprehensive care strategy, not a stand-alone prescription," Chief Operating Officer Lara Dodo said in the news release. "Dario now combines AI-powered engagement, connected monitoring, personalized coaching and provider-backed clinical care in a single platform, wherever the member comes to us from."
The company said clinical eligibility for GLP-1 therapy will be determined solely by licensed healthcare providers following a comprehensive medical history review and clinical evaluation consistent with FDA labeling, evidence-based clinical guidelines and applicable state and federal requirements.
GLP-1 Therapies Continued to Expand Across Chronic Disease Care
According to a July 9 report from Precedence Research, the global GLP-1 market was valued at US$58.40 billion in 2025 and was projected to reach US$66.46 billion in 2026. The firm said the market was "driven by the expanding clinical indication of these therapies," which had evolved from treating Type 2 diabetes to chronic weight management and cardiovascular risk reduction. It also identified the shift toward oral therapies as a major trend, stating that oral formulations "directly remove patient barriers" and offer "robust, clinically meaningful weight reduction along with notable cardiometabolic benefits."
A July 17 report from Straits Research likewise described expanding demand for GLP-1 receptor agonists, citing "the rising prevalence of diabetes and obesity, expanding treatment indications, and growing awareness of metabolic health." The firm wrote that the market was moving beyond glucose control into "comprehensive cardiometabolic treatment options" as clinical evidence expanded across cardiovascular, renal and weight management applications. Straits Research also said that broader reimbursement for anti-obesity medications was increasing patient access, while manufacturers continued investing in production capacity to address demand, even as the industry remained "highly exposed to supply chain disruptions" because of specialized manufacturing and cold-chain logistics.
Commercial Rollout and Platform Expansion
Dario said commercial availability of the Integrated GLP-1 Program is expected in Fall 2026, with revenue contribution anticipated later in 2026 and ramping through 2027.
The company stated that the rollout will include three commercial channels consisting of direct-to-consumer availability through the MyDario Shop, health plan marketplaces and employer B2B2C programs. For employers that carve out GLP-1 medications for obesity, Dario said the offering can be combined with its cardiometabolic programming. The company also said it offers a cost-sharing option with an Rx savings card for employers that wish to maintain a level of subsidy.
According to Dario's July 2026 corporate presentation, the company is expanding beyond digital engagement into provider-backed care that connects monitoring, AI-driven triage and clinical intervention. The presentation states that the expanded model includes a 50-state provider network, prescribing capability, diagnostic testing and escalation from AI to clinicians.
Streetwise Ownership Overview*
DarioHealth Corp. (DRIO:NASDAQ)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 11/18/19 | DRIO:NASDAQ | 20 | DRIO:NASDAQ | 1 |
| 03/20/13 | LSYI:NASDAQ | 1 | DRIO:NASDAQ | 1 |
The presentation also states that Dario's platform supports more than six chronic conditions, including diabetes, hypertension, weight management, GLP-1 support, behavioral health and musculoskeletal care, while using more than 13 billion proprietary healthcare data points to personalize member care.
Ownership and Share Information1
DarioHealth Corp. has a market cap of US$51.41 million, with 7.3 million shares outstanding.
The company's 52-week range is US$5.84-US$17.74.
Institutions own 39.4% of shares, while Strategic Investors own 7.5%.
Management & Insiders own 4.5% of shares, and the remaining 48.6% of shares are held by Retail.
Frequently Asked Questions
What is DarioHealth's new Integrated GLP-1 Program?
DarioHealth's Integrated GLP-1 Program combines its chronic care platform with provider-backed clinical care, including medical evaluations, prescribing of FDA-approved GLP-1 medications where clinically appropriate, and ongoing clinical oversight within a single platform.
How does DarioHealth's GLP-1 program work?
According to the company, members receive clinical evaluation from licensed healthcare providers, access to GLP-1 prescriptions when clinically appropriate, and ongoing support through Dario's platform, which also includes AI-powered engagement, connected monitoring, nutrition support, and behavioral coaching.
Who can prescribe GLP-1 medications through DarioHealth?
DarioHealth said clinical eligibility is determined solely by licensed healthcare providers following a comprehensive medical history review and clinical evaluation consistent with FDA labeling, evidence-based clinical guidelines, and applicable state and federal requirements.
When will DarioHealth's Integrated GLP-1 Program become available?
The company said the program is expected to become commercially available beginning in Fall 2026 through its direct-to-consumer offering, with additional availability through health plan marketplaces and employer programs.
Where will DarioHealth offer its GLP-1 program?
According to the company, the program is expected to be available through three channels: the MyDario Shop, health plan marketplaces, and employer B2B2C programs.
What is Beluga Health's role in DarioHealth's GLP-1 program?
Beluga Health provides the licensed healthcare provider network supporting medical evaluations, prescribing where clinically appropriate, and ongoing clinical oversight within DarioHealth's platform.
Does DarioHealth prescribe FDA-approved GLP-1 medications?
Yes. The company said licensed healthcare providers may prescribe FDA-approved GLP-1 medications when they determine a member meets established clinical criteria.
What chronic conditions does DarioHealth support?
According to the company, its integrated platform supports people living with diabetes, hypertension, weight management needs, musculoskeletal conditions, and behavioral health conditions.
How does artificial intelligence fit into DarioHealth's GLP-1 platform?
The company said its DarioIQ AI engine supports member engagement and uses blinded member interaction data generated across the platform to help optimize outcomes and payer cost savings.
Why are employers changing GLP-1 coverage strategies?
According to DarioHealth, employers and health plans are moving away from broad GLP-1 coverage toward clinically managed models that verify eligibility, guide appropriate prescribing, and integrate chronic condition management.
How many people have used DarioHealth's digital marketplace?
The company said its MyDario Shop has served more than 1 million consumers over the past three years.
What is DarioHealth (NASDAQ: DRIO)?
DarioHealth is an AI-powered healthcare technology company whose platform combines connected devices, personalized member engagement, AI-driven insights, and provider-backed clinical care to support chronic condition management.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals and Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- DarioHealth Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
